Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Synerx Pharma and Verelan PM 300 mg Verapamil HCl Extended Release Capsules Controlled-Onset in Healthy Aduly Volunteers Under Fed Conditions

NCT01467687 is registered in ClinicalTrials.gov with Synerx Pharma, LLC as lead sponsor.

NCT NCT01467687
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01467687 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Synerx Pharma and Verelan PM 300 mg Verapamil HCl Extended Release Capsules Controlled-Onset in Healthy Aduly Volunteers Under Fed Conditions
Lead sponsor
Synerx Pharma, LLC
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2007
Completion date
August 31, 2007
Enrollment
58 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

healthy